Methods for therapeutic trials in COPD: Lessons from the TORCH trial

European Respiratory Journal

Volumn 34, Issue 5, 2009, Pages 1018-1023

  Keene, O N ^a   Vestbo, J ^b,e   Anderson, J A ^a   Calverley, P M A ^c   Celli, B ^f   Ferguson, G T ^g   Jenkins, C ^h   Jones, P W ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f ST ELIZABETH'S MEDICAL CENTER   (United States)

^g Pulmonary Research Institute of Southeast Michigan   (United States)

^h WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Bias; Chronic obstructive pulmonary disease; Exacerbations; Intention to treat; Withdrawal

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; SALMETEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; METHODOLOGY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 71049160113     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00122608     Document Type: Review

References (24)

1. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
2. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Resp J 2008; 31: 1-8.
3. Aaron SD, Vandemheen K, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555. (Pubitemid 351650535)
4. Vestbo J, TORCH Study Group, The TORCH (Towards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004; 24: 206-210. (Pubitemid 39139786)
5. Pocock SJ. Clinical Trials: A Practical Approach. Chichester, Wiley, 1983; p. 182.
6. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Statist Med 1999; 18: 1905-1942.
7. Moher D, Schulz KF, Altman D, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-1991. (Pubitemid 32366951)
8. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694. (Pubitemid 32322245)
9. Calverley PMA, Spencer S, Willits LR, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124: 1350-1356. (Pubitemid 37290045)
10. Keene ON, Jones MRK, Lane PW, et al. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat 2007; 6: 89-97.
11. Keene ON, Calverley PMA, Jones PW, et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 2008; 32: 17-24.
12. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatment. I: ethical and scientific issues. Ann Intern Med 2000; 133: 455-463.
13. Temple R. Special study designs: early escape, enrichment, studies in non-responders. Commun Statist Theory Meth 1994; 23: 499-531.
14. Kay R. Some fundamental statistical concepts in clinical trials and their application in herpes zoster. Antivir Chem Chemother 1995; 6: Suppl. 1, 28-33.
15. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981; 68: 373-379.
16. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100-1120.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007. Available from: www.goldcopd.org
18. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007; 356: 2211-2212.
19. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
20. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-98.
21. Lubsen J, Pocock SJ. Factorial trials in cardiology: pros and cons. Eur Heart J 1994; 15: 585-588. (Pubitemid 24186322)
22. Wedzicha JA, Calverley PMA, Seemungal TA, et al. Letter to the editor. Am J Respir Crit Care Med 2008; 178: 544.
23. Food and Drug Administration. Pulmonary-Allergy Drugs Advisory Committee May 1 2007 briefing information. www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4298b1-01-FDA.pdf Date last updated: April 24, 2007. Date last accessed: June 5, 2008.
24. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.